Neda Rajaeean

Neda Rajaeean

Auto-generated profile, based on publicly available information

Neda Rajaeean

Pfizer Pharma GmbH, Berlin, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2024 in Pharmaceutical Medicine
Verified
Journal Article
Open access
PDF file
EFEmma Fröling
Emma Fröling
NRNeda Rajaeean
Neda Rajaeean
KHKlara Sonnie Hinrichsmeyer
Klara Sonnie Hinrichsmeyer
DDDina Domrös-Zoungrana
Dina Domrös-Zoungrana
JUJohannes Nico Urban
Johannes Nico Urban
CLChristian Lenz
Christian Lenz
The advent of artificial intelligence (AI) revolutionizes the ways of working in many areas of business and life science. In Medical Affairs (MA) departments of the pharmaceutical industry AI holds great potential for positively influencing the medical mission of identifying and addressing unmet medical needs and care gaps, and fostering solutions that improve the egalitarian and unbiased access of patients to treatments worldwide. Given the essential position of MA in corporate interactions with various healthcare stakeholders, AI offers broad possibilities to support strategic decision-making and to pioneer novel approaches in medical stakeholder interactions. By analyzing data derived from the healthcare environment and by streamlining operations in medical content generation, AI advances data-based prioritization and strategy execution. In this review, we discuss promising AI-based solutions in MA that support the effective use of heterogenous information from observations of the healthcare environment, the enhancement of medical education, and the analysis of real-world data. For a successful implementation of such solutions, specific considerations partly unique to healthcare must be taken care of, for example, transparency, data privacy, healthcare regulations, and in predictive applications, explainability.